Press Release

CSRxP Applauds PhRMA’s Newfound Commitment to R&D

May 9, 2017

“If PhRMA’s members are serious about their commitment to affordability, we invite them to join us in supporting common-sense, bipartisan reforms like the CREATES and FAST Generics Acts that address equally-egregious, though less-publicized, anticompetitive abuses as the ones that prompted this change in policy.” Read More

CSRxP Statement on President Trump’s Meeting With Big Pharma Executives

May 8, 2017

“Transparency is one of the keys to market-based reforms that will lead to lower prices and ensure that taxpayers receive a real return on their investment." Read More

CSRxP Launches National Campaign to Hold Big Pharma Accountable

May 2, 2017

CSRxP has launched a national campaign as part of a multi-million-dollar effort to hold Big Pharma accountable for their out-of-control prescription drug prices. Because Big Pharma blocks competition to maintain monopolies on medicines, they can set any price they want. Read More

CSRxP Applauds Introduction of FAST Generics Act

Apr 7, 2017

"The FAST Generics Act represents market-based reforms that will increase competition and ensure that lifesaving medications can safely reach patients at an affordable price." Read More

American Academy of Family Physicians Joins CSRxP

Apr 6, 2017

American Academy of Family Physicians Joins CSRxP The Campaign for Sustainable Read More

CSRxP Calls For Further Action on Rx Prices

Mar 3, 2017

"We must ‘bring down the artificially high price of drugs and bring them down immediately.’ That’s what the President said in his address to Congress – and the American people agree. Read More

CSRxP Applauds Trump Administration’s Focus on Lowering Prescription Drug Prices

Jan 31, 2017

We applaud President Trump for making the out-of-control prices of prescription drugs a priority in his Administration. Read More

CSRxP on PhRMA’s Multimillion-Dollar PR Campaign

Jan 23, 2017

"No amount of advertising will make hardworking families forget the consequences of their out-of-control drug costs." Read More

High-Priced Drugs Driving Increased Taxpayer Spending, HHS Report Shows

Jan 5, 2017

A new HHS Office of the Inspector General report finds that high-priced prescription drugs are threatening the sustainability of the taxpayer-funded Medicare Part D program. Read More

CSRxP Blasts Novo Nordisk’s Plans for Prescription Price Hikes

Dec 7, 2016

Based on Novo Nordisk’s announcement, it is clear that the company will continue to hike insulin prices, despite the financial burdens already facing patients. “The prescription drug market is clearly broken when limiting yearly price increases to ten percent is considered bighearted,” said John Rother. Read More

CSRxP Praises President-Elect’s Commitment to Lower Prescription Drug Prices

Dec 7, 2016

"We are encouraged to see the president-elect is ready to take action. We look forward to working with the new Administration and the new Congress to find solutions to fix the broken prescription drug market, and to help make life-saving medications more affordable for the patients who need them.” Read More

Straight Talk for Pharma

Dec 7, 2016

The drug industry is front and center in a national dialogue. How do we make sure patients around the world can get the medicines they need? Can we balance costs and the need for innovation? Pharma leaders answer Forbes’ questions – and yours. Read More